$IQST
iQSTEL Inc Stock $iqst

$iqst Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000166357723000520 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$47.25M	$39.76M
YoY Change	67.88%	81.24%
Cost Of Revenue	$45.61M	$38.73M
YoY Change	57.27%	87.81%
Gross Profit	$1.642M	$1.029M
YoY Change	-292.36%	-21.78%
Gross Profit Margin	3.48%	2.59%
Selling, General & Admin	$1.345M	$860.0K
YoY Change	7.41%	-19.67%
% of Gross Profit	81.91%	83.62%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$28.74K	$30.00K
YoY Change	-0.55%	3.99%
% of Gross Profit	1.75%	2.92%
Operating Expenses	$1.371M	$957.8K
YoY Change	6.98%	-23.75%
Operating Profit	$271.6K	$70.75K
YoY Change	-112.72%	20.3%
Interest Expense	-$40.59K	$10.00K
YoY Change	-98.47%	-371.0%
% of Operating Profit	-14.94%	14.13%
Other Income/Expense, Net	-$88.29K	-$24.84K
YoY Change	-509.32%	-21.13%
Pretax Income	$55.12K	$50.00K
YoY Change	-101.08%	83.07%
Income Tax	$0.00
% Of Pretax Income	0.0%
Net Earnings	-$124.1K	-$62.01K
YoY Change	-97.51%	-9.95%
Net Earnings / Revenue	-0.26%	-0.16%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	171.5M shares	166.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.363M	$2.000M
YoY Change	2.5%	54.44%
Cash & Equivalents	$1.363M	$2.001M
Short-Term Investments
Other Short-Term Assets	$759.1K	$890.0K
YoY Change	1494.64%	62.96%
Inventory	$27.12K	$27.12K
Prepaid Expenses	$1.449M	$1.697M
Receivables	$12.54M	$7.636M
Other Receivables	$1.031M	$1.230M
Total Short-Term Assets	$15.72M	$11.79M
YoY Change	144.22%	91.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$523.0K	$463.0K
YoY Change	30.42%	18.19%
Goodwill	$5.172M	$5.172M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$641.8K	$156.4K
YoY Change	45.81%	-62.17%
Total Long-Term Assets	$6.436M	$6.336M
YoY Change	5.29%	4.26%
TOTAL ASSETS
Total Short-Term Assets	$15.72M	$11.79M
Total Long-Term Assets	$6.436M	$6.336M
Total Assets	$22.16M	$18.12M
YoY Change	76.55%	48.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.966M	$4.015M
YoY Change	31.56%	109.82%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$101.9K	$180.0K
YoY Change	7.97%
Long-Term Debt Due	$752.6K	$252.8K
YoY Change	697.75%	-371.21%
Total Short-Term Liabilities	$13.84M	$9.914M
YoY Change	114.53%	257.91%
LONG-TERM LIABILITIES
Long-Term Debt	$99.10K	$91.02K
YoY Change	-8.37%	-10.41%
Other Long-Term Liabilities	$169.7K	$160.0K
YoY Change	10.05%	10.44%
Total Long-Term Liabilities	$268.8K	$246.9K
YoY Change	2.46%	0.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.84M	$9.914M
Total Long-Term Liabilities	$268.8K	$246.9K
Total Liabilities	$13.73M	$10.16M
YoY Change	104.53%	236.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$26.08M	-$25.96M
YoY Change	6.45%	33.05%
Common Stock	$172.1K	$170.2K
YoY Change	6.52%	12.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.424M	$8.528M
YoY Change
Total Liabilities & Shareholders Equity	$22.16M	$18.12M
YoY Change	76.55%	48.34%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$124.1K	-$62.01K
YoY Change	-97.51%	-9.95%
Depreciation, Depletion And Amortization	$28.74K	$30.00K
YoY Change	-0.55%	3.99%
Cash From Operating Activities	-$1.054M	$290.0K
YoY Change	281.59%	-640.94%
INVESTING ACTIVITIES
Capital Expenditures	$60.05K	$30.00K
YoY Change	134.75%	-176.39%
Acquisitions
YoY Change
Other Investing Activities	$67.49K	-$30.00K
YoY Change	-190.35%	-87.99%
Cash From Investing Activities	$7.450K	-$60.00K
YoY Change	-107.43%	-79.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	384.0K	660.0K
YoY Change	-4.01%
NET CHANGE
Cash From Operating Activities	-1.054M	290.0K
Cash From Investing Activities	7.450K	-60.00K
Cash From Financing Activities	384.0K	660.0K
Net Change In Cash	-662.4K	890.0K
YoY Change	-2912.65%	-359.8%
FREE CASH FLOW
Cash From Operating Activities	-$1.054M	$290.0K
Capital Expenditures	$60.05K	$30.00K
Free Cash Flow	-$1.114M	$260.0K
YoY Change	269.14%	-1913.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001527702
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022Q3	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1		usd
	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
CY2023Q3	IQST	Stock Issued During Period Value Series B Preferred Issued As Dividend StockIssuedDuringPeriodValueSeriesBPreferredIssuedAsDividend		usd
CY2023Q3	IQST	Dividend To Non Controlling Interest DividendToNonControllingInterest		usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets		usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes		usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	IQST	Series B Preferred Stock Issued As Dividend SeriesBPreferredStockIssuedAsDividend		usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
	IQST	Stock Issued During Period Value Acquisitions To Be Issued StockIssuedDuringPeriodValueAcquisitionsToBeIssued		usd
	IQST	Common Stock Issued For Settlement Of Debt Value1 CommonStockIssuedForSettlementOfDebtValue1		usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue		usd
CY2022Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable		usd
CY2023Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	IQST	Weighted Average Remaining Life Of Warrants Granted In Period WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod
	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Increased By Vwap Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Of Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2023Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm
	us-gaap	Dividends Dividends		usd
CY2022	us-gaap	Dividends Dividends		usd
CY2023Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet		usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
	IQST	Revaluation Of Derivative Liabilities RevaluationOfDerivativeLiabilities		usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55984
	dei	Entity Registrant Name EntityRegistrantName	iQSTEL Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2808620
	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Aragon Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 375
	dei	Entity Address City Or Town EntityAddressCityOrTown	Coral Gables
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33134
	dei	City Area Code CityAreaCode	954
	dei	Local Phone Number LocalPhoneNumber	951-8191
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	171529630	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2001320	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1329389	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7635615	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4209125	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	27121	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	26124	usd
CY2023Q3	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	427194	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	326324	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1696944	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	545628	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	11788194	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6436590	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	463036	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401021	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99592	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99592	usd
CY2023Q3	us-gaap	Goodwill Goodwill	5172146	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5172146	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	444504	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	440135	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	156388	usd
CY2023Q3	us-gaap	Assets Assets	18123860	usd
CY2022Q4	us-gaap	Assets Assets	12549484	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4014529	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2254636	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5204219	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2482352	usd
CY2023Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent	252779	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	94342	usd
CY2023Q3	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	238291	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	235949	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	177666	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1357787	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9914097	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6451679	usd
CY2023Q3	us-gaap	Loans Payable To Bank LoansPayableToBank	91018	usd
CY2022Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	108150	usd
CY2023Q3	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	155909	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	154238	usd
CY2023Q3	us-gaap	Liabilities Liabilities	10161024	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6714067	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	170232	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	161595	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34350837	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31136120	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25960018	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24504395	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33485	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33557	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	8527607	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6759794	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-564771	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-924377	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7962836	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5835417	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18123860	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12549484	usd
CY2023Q3	us-gaap	Revenues Revenues	39757203	usd
CY2022Q3	us-gaap	Revenues Revenues	21936634	usd
	us-gaap	Revenues Revenues	97248561	usd
	us-gaap	Revenues Revenues	65055661	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	38728682	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	20621674	usd
	us-gaap	Cost Of Revenue CostOfRevenue	94218838	usd
	us-gaap	Cost Of Revenue CostOfRevenue	62410367	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1028521	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1314960	usd
	us-gaap	Gross Profit GrossProfit	3029723	usd
	us-gaap	Gross Profit GrossProfit	2645294	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	957768	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1256147	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3529218	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3390097	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	957768	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1256147	usd
	us-gaap	Operating Expenses OperatingExpenses	3529218	usd
	us-gaap	Operating Expenses OperatingExpenses	3390097	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	70753	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	58813	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-499495	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-744803	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2607	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	43219	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3126	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	38591	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32505	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-71027	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-105714	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-54247	usd
CY2023Q3	IQST	Interest Expense2 InterestExpense2	34219	usd
CY2022Q3	IQST	Interest Expense2 InterestExpense2	3693	usd
	IQST	Interest Expense2 InterestExpense2	54322	usd
	IQST	Interest Expense2 InterestExpense2	22417	usd
CY2023Q3	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	39273	usd
	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	381848	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24844	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31501	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224938	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38073	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	45909	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	27312	usd
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-274557	usd
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-782876	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	45909	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	27312	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-274557	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-782876	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	107922	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	96175	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	364586	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	192137	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-62013	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-68863	usd
	us-gaap	Net Income Loss NetIncomeLoss	-639143	usd
	us-gaap	Net Income Loss NetIncomeLoss	-975013	usd
CY2023Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	-816480	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	-816480	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-878493	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-68863	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1455623	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-975013	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	45909	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	27312	usd
	us-gaap	Profit Loss ProfitLoss	-274557	usd
	us-gaap	Profit Loss ProfitLoss	-782876	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	4428	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	1096	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-142	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	2503	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	41481	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	26216	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-274415	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-785379	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	105753	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	95638	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	364656	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	190911	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64272	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69422	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-639071	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-976290	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	168185122	shares
CY2022Q3	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	151750426	shares
	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	165640341	shares
	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	150057315	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6759794	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	400000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11230	usd
CY2023Q1	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	804	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-363185	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7048901	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6900	usd
CY2023Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	1527	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-213945	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6843383	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12815	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1000000	usd
CY2023Q3	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	735681	usd
CY2023Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-2259	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-62013	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	8527607	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7416911	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	41139	usd
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-196	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-554970	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	7902884	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	30490	usd
CY2022Q2	IQST	Stock Issued During Period Value Acquisitions To Be Issued StockIssuedDuringPeriodValueAcquisitionsToBeIssued	1550000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	325000	usd
CY2022Q2	IQST	Common Stock Payable Value CommonStockPayableValue	18900	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	500000	usd
CY2022Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-522	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-351180	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9975572	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20500	usd
CY2022Q3	IQST	Common Stock Issued For Settlement Of Debt Value1 CommonStockIssuedForSettlementOfDebtValue1	80674	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	32500	usd
CY2022Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-559	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-68863	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	10039824	usd
	us-gaap	Profit Loss ProfitLoss	-274557	usd
	us-gaap	Profit Loss ProfitLoss	-782876	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30945	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	111029	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1344	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	26299	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	103246	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	91221	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	21404	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	7407	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-381848	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3422703	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	832263	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-997	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-26124	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1057311	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	31714	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-69948	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	5143	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2604856	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-97373	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1870972	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	50636	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-434701	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1488901	usd
	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	-1814132	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	164715	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86491	usd
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	189767	usd
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	1000	usd
	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	13899	usd
	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	400	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-340583	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1901223	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	150000	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	9006	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	232018	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1100000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1150000	usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	250000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	500000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-86238	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1454756	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1367982	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7541	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-17690	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	671931	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2039832	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1329389	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3334813	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2001320	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1294981	usd
	us-gaap	Interest Paid Net InterestPaidNet	25941	usd
	us-gaap	Interest Paid Net InterestPaidNet	3333	usd
	IQST	Series B Preferred Stock Issued As Dividend SeriesBPreferredStockIssuedAsDividend	816480	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	357500	usd
	IQST	Stock Issued During Period Value Acquisitions To Be Issued StockIssuedDuringPeriodValueAcquisitionsToBeIssued	1550000	usd
	IQST	Common Stock Issued For Settlement Of Debt Value1 CommonStockIssuedForSettlementOfDebtValue1	80674	usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	975939	usd
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2011-06-24
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zkTGMLssrB36" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	176121	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	120139	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	871930	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	26600	usd
CY2023Q1	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	21000	usd
CY2022Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	21000	usd
CY2023Q1	us-gaap	Income Tax Receivable IncomeTaxReceivable	393	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	389	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	357500	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	357500	usd
CY2023Q1	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	250000	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1696944	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	545628	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1223046	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1057650	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	-760010	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	-656629	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	463036	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401021	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	103246	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	91221	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	351297	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	202492	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	343797	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	202492	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	252779	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	94342	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	91018	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108150	usd
CY2023Q3	us-gaap	Loans Payable LoansPayable	238291	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	235949	usd
CY2023Q3	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	238291	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	235949	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	246927	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6436590	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6112894	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6451679	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	262388	usd
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_80B_eus-gaap--DerivativesReportingOfDerivativeActivity_zvYu7bUesoeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b>NOTE 8 – WARRANTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On April 5, 2022, we entered into a Common Stock Purchase Option Agreement with Apollo Management Group, Inc (Holder) to subscribe for and purchase from the Company, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_z1XhnpTzNNol">4,800,000</span> shares of Common Stock with an exercise price per share of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_z2WPkEztwap">$2.00</span>; and an initial exercisable date on <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zCEU7168RRHi">September 30, 2022</span>. The purchase price of this option was <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_z4FYSuqIqxje">$500,000</span>. The Company determined that the warrants had a fixed monetary value with a variable number of shares at inception and categorized the warrants as a liability in the accompanying consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><span id="xdx_900_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternatives_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zgJbpCVtR90c">The Holder and the Company agreed that the Holder had the right and the obligation to exercise, on a cashless basis, $1,000,000 of the Options not later than October 15, 2022. Thereafter, the Holder shall undertake to exercise not less than (i) $400,000 of the Options on a “cash basis” not later than the later of (y) <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221114__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zZXykpHMM1Wg">November 14, 2022</span> or (z) the date on which there is an effective registration statement permitting the issuance of the Option Shares to or resale of the Option Shares by the Holder and (ii) an additional <span id="xdx_905_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_iI_c20221214__us-gaap--DebtInstrumentAxis__custom--ApolloOptionAdditionalMember_zia0wKdu6X83">$400,000</span> of the Options on a “cash basis” not later than the latest of (x) thirty (30) days following the exercise of the Option under subsection (i), above, (y) December 14, 2022, or (z) the date on which there is an effective registration statement permitting the issuance of the Option Shares to or resale of the Option Shares by the Holder. From and after the occurrence of the three above-referenced exercises, each additional exercise of Options hereunder shall be in an amount not less than <span id="xdx_90D_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_iI_c20221214__us-gaap--DebtInstrumentAxis__custom--ApolloOptionEachAdditionalMember_zHZLqGvjlRjb">$200,000</span> and exercised only on a cash basis.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><span id="xdx_90A_eus-gaap--DebtInstrumentCallFeature_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--ApolloManagementGroupMember_zh3bQrDhV0yj">The Holder’s obligation to exercise each specified portion of this option on the specific dates above is subject to the volume-weighted average price (“VWAP”, market value), being not less than $0.20 per share on the relevant option exercise date. Adjusted option shares at VWAP of $0.20 shall be 48,000,000 shares.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">A summary of activity regarding warrants issued as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zhL7HEQVXHuj" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - NOTE 8 - WARRANTS - Schedule of Warrant Summary (Details)"> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Warrants Outstanding</b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="3"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Shares</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Weighted Average Remaining Contractual life (in years)</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; padding-left: 5.4pt">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231_zfu8QcekrSvf">23,112,575</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231_z7LaIKot9aOh">0.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_zqJ81Zpyuiq5">0.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230930_z50J13La7khf"><span style="-sec-ix-hidden: xdx2ixbrl1116">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930_zw0xkBoHtUYd"><span style="-sec-ix-hidden: xdx2ixbrl1117">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod_d0_c20230101__20230930_zjQgFYUHYvu5"><span style="-sec-ix-hidden: xdx2ixbrl1118">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Increase in number of warrants by VWAP</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20230101__20230930_zsCJspDyutz9">5,262,465</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--IncreaseInNumberOfWarrantsWeightedAverageExercisePrice_c20230101__20230930_zEbYJBPTPPY8">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife_d0_c20230101__20230930_z4IrAS15mMGi"><span style="-sec-ix-hidden: xdx2ixbrl1121">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230930_zBQOCCvjdfQ6">10,294,119</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930_zsj5DFdS4TVc">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20230930_z3cjQvsseNQj">0.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20230930_zyKV1nhK2x55">18,080,921</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20230930_zMYeRw9bCyD1"><span style="-sec-ix-hidden: xdx2ixbrl1126">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited_d0_c20230101__20230930_zoZgCAHWx2xb"><span style="-sec-ix-hidden: xdx2ixbrl1127">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding, September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20230930_zwjVieX0oPEi"><span style="-sec-ix-hidden: xdx2ixbrl1128">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20230930_ztGpCap0LWli"><span style="-sec-ix-hidden: xdx2ixbrl1129">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230930_zi2fiLSKYyF9"><span style="-sec-ix-hidden: xdx2ixbrl1130">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	23112575	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.17
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y9M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	5262465	shares
	IQST	Increase In Number Of Warrants Weighted Average Exercise Price IncreaseInNumberOfWarrantsWeightedAverageExercisePrice	0.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	10294119	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y8M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	18080921	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0467	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0555	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0006	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0473	pure
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	1357787	usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	975939	usd
	us-gaap	Debt Securities Held To Maturity Transfer Derivative Hedge Gain Loss DebtSecuritiesHeldToMaturityTransferDerivativeHedgeGainLoss	381848	usd
	IQST	Revaluation Of Derivative Liabilities RevaluationOfDerivativeLiabilities	381848	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	381848	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8635884	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	180000	shares
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	30945	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1150000	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	170231395	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	170231395	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161595511	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161595511	shares
CY2023Q3	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	427194	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	326324	usd
CY2023Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	402000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	405000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	30945	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	92130	usd
CY2023Q3	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	65627	usd
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	79628	usd
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	79628	usd
CY2023Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
	us-gaap	Operating Lease Expense OperatingLeaseExpense	4048	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	56405	usd
CY2023Q3	us-gaap	Revenues Revenues	39757203	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	38728682	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1028521	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	957768	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	70753	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24844	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	45909	usd
CY2022Q3	us-gaap	Revenues Revenues	21936634	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	20621674	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1314960	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1256147	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	58813	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31501	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	27312	usd
	us-gaap	Revenues Revenues	97248561	usd
	us-gaap	Cost Of Revenue CostOfRevenue	94218838	usd
	us-gaap	Gross Profit GrossProfit	3029723	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3529218	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-499495	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224938	usd
	us-gaap	Profit Loss ProfitLoss	-274557	usd
	us-gaap	Revenues Revenues	65055661	usd
	us-gaap	Cost Of Revenue CostOfRevenue	62410367	usd
	us-gaap	Gross Profit GrossProfit	2645294	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3390097	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-744803	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-38073	usd
	us-gaap	Profit Loss ProfitLoss	-782876	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	11788194	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	6335666	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9914097	usd

Files In Submission

Name	View Source	Status
0001663577-23-000520-index-headers.html	Edgar Link	pending
0001663577-23-000520-index.html	Edgar Link	pending
0001663577-23-000520.txt	Edgar Link	pending
0001663577-23-000520-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
iqst-20230930.xsd	Edgar Link	pending
iqst10q093023.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
iqst-20230930_pre.xml	Edgar Link	unprocessable
iqst-20230930_lab.xml	Edgar Link	unprocessable
iqst10q093023_htm.xml	Edgar Link	completed
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
iqst-20230930_cal.xml	Edgar Link	unprocessable
iqst-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IQST
iQSTEL Inc Stock $iqst

2023 Q4 Form 10-Q Financial Statement

#000166357723000520 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST iQSTEL Inc Stock $iqst

2023 Q4 Form 10-Q Financial Statement

#000166357723000520 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST
iQSTEL Inc Stock $iqst